MAIA reports Q3 net loss $4.9M; THIO shows 100% DCR in second-line NSCLC, FDA IND cleared

MAIA Biotechnology, Inc.

2023-Q3 EPS reported -$1.08

Cash $6.1M at Sep 30, 2023 vs $10.9M at Dec 31, 2022; net loss $4.9M ($0.36/share) unchanged YoY.
THIO-101 Phase 2 trial achieved 100% disease control rate in second-line NSCLC, exceeding standard of care 53-64%.
FDA cleared THIO IND for U.S. enrollment in THIO-101; 49 patients dosed, enrollment pace exceeding similar trials.
First two subjects on trial reported long-term survival of 14.6 and 12.5 months with no new anti-cancer treatment.
R&D expenses $2.6M (up from $2.3M); G&A $2.4M (up from $1.7M) due to professional fees and investor relations.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MAIA Biotechnology, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023, EPS $0.36 per share.

Period: the third quarter ended September 30, 2023
Net income: Net loss was approximately $4.9 million, or $0.36 per share, for the quarter ended September 30, 2023
EPS: $0.36 per share
Result: reported results

Exact text from the filing

MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended September 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-271933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.